Hepatocyte growth factor (HGF) can be produced by various cells and elicits multiple biological responses such as motility, proliferation, morphogenesis and survival in a cell type-dependent fashion. Apart from its physiological importance, HGF may contribute to many organ diseases \[[@CIT0001]--[@CIT0003]\]. We have already shown that conversely to routinely measured biomarkers of myocardial injury, human HGF (hHGF) increases to high levels in the very early phase of acute coronary syndrome (ACS) and then decreases rapidly during the first 24 h of ACS \[[@CIT0004]\]. As described in our previous article, we measured hHGF concentration only twice, namely at admission and 24 h later \[[@CIT0004]\]. We decided to establish the dynamicity of hHGF level changes on the first day of myocardial injury and to determine the usefulness of its measurement in the case of untimely complications.

In 4 patients with ST-segment elevation myocardial infarction (STEMI) and in 2 patients with non ST-segment elevation myocardial infarction (NSTEMI), who were eligible for coronary angiography and, possibly, primary percutaneous coronary intervention (PPCI), hHGF measurements were repeated 10 times during the first day of ACS and once at discharge from hospital ([Figure 1](#F0001){ref-type="fig"}). Each subject expressed their informed consent to participate in the study. Patients' informed consent and the protocol of the study were approved by the Institutional Local Ethics Committee. Patients' detailed particulars are presented in the [Table I](#T0001){ref-type="table"}.
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###### 

Detailed description of six patients with ACS

  --------------------------------------------------- --------------------------------- -------- ------------------- -------- -------------------- ----------------------------
  **Patient**                                         1                                 2        3                   4        5                    6
  **Age \[years\]**                                   70                                56       66                  61       72                   39
  **Gender**                                          Male                              Male     Male                Male     Female               Male
  **Duration of chest pain \[min\]**                  370                               570      900                 160      125                  120
  **Type of ACS and localization of MI (wall)**       STEMI inferior and posterior MI   NSTEMI   STEMI anterior MI   NSTEMI   STEMI posterior MI   lateral MI
  **cTnI \[ng/ml\] -- first day of ACS**              0.23                              6.54     4.78                0.11     0.01                 0.03
  **cTnI \[ng/ml\] -- second day of ACS**             14.99                             11.55    18.98               9.25     1.18                 24.24
  **PPCI**                                            Yes                               No       Yes                 No       Yes                  Yes
  **Infarct-related artery**                          CRX                                        LAD                          CRX                  CRX
  **Stent implantation**                              Yes                               No       Yes                 No       Yes                  No
  **Clopidogrel in loading dose 600mg before PPCI**   Yes                               Yes      Yes                 Yes      Yes                  Yes
  **Aspirin \[mg\]**                                  300                               150      300                 300      300                  300
  **Abciximab during PPCI**                           Yes                               No       Yes                 No       No                   No
  **Complications during acute stage of ACS**         CA (VF)                           No       No                  No       No                   CRX reocclusion during PCI
  **EF -- second day of ACS \[%\]**                   46                                55       60                  60       70                   50
  --------------------------------------------------- --------------------------------- -------- ------------------- -------- -------------------- ----------------------------

ACS -- acute coronary syndrome, MI -- myocardial infarction, STEMI -- ST-segment elevation myocardial infarction, NSTEMI -- non-ST-segment elevation myocardial infarction, cTnI -- cardiac troponin I with diagnostic cut-point 0.1 ng/ml, PPCI -- primary percutaneous coronary intervention, CRX -- circumflex coronary artery, LAD -- left descending coronary artery, CA -- cardiac arrest, VF -- ventricular fibrillation, EF -- ejection fraction measured by echocardiography

Human HGF was determined in plasma using the Quantikine Elisa kit from R&D Systems, Minneapolis, MN, USA. The mean value of hHGF evaluated in EDTA plasma using the Quantikine Elisa kit and presented in the manufacturer\'s brochure as a reference value was 787 pg/ml (range: 469-1113 pg/ml).

In the first measurement, as illustrated in the [Figure 1](#F0001){ref-type="fig"}, a marked increase in hHGF levels was observed in STEMI patients. Very high values (maximally about 20 000 pg/ml) were reduced to almost normal values within 5 h from the first measurement. In NSTEMI patients, even in the first assessment we did not observe very high levels of hHGF, and during the first 24 h of ACS, hHGF levels were stable. Contrary to patients with an uncomplicated acute course of STEMI, 2 patients with serious cardiovascular events in the acute stage of myocardial infarction, namely cardiac arrest and early reocclusion of the coronary artery, revealed a second increase of hHGF levels during the first 24 h of ACS ([Figure 1](#F0001){ref-type="fig"}).

We have already revealed that during the first 24 h of ACS HGF showed properties comparable with troponin I and N-terminal prohormone B-type natriuretic peptide (NT-proBNP), which are routinely used as markers of ischemic myocardial damage and risk stratification in patients with impaired left ventricular function \[[@CIT0004]--[@CIT0007]\]. Troponin I reached peak values and confirmed myocardial necrosis when hHGF levels were already at a normal level \[[@CIT0004]\]. Now, the very high hHGF values were observed in patients admitted within the first 2 h of STEMI presentation (patients 5 and 6) ([Figure 1](#F0001){ref-type="fig"}, [Table I](#T0001){ref-type="table"}). In this aspect, the observed changes in hHGF concentrations in the early stage of myocardial infarction are a great advantage of this diagnostic method.

The time from the onset of ACS symptoms to treatment, effectiveness of reperfusion therapy measured as grade of flow in the infarct-related artery, and medical therapy applied during PPCI influence the levels of biomarkers \[[@CIT0005], [@CIT0008]\]. We supposed that in our study hHGF re-elevation was connected with acute complications of ACS. Due to the small number of patients we cannot definitely prove this relationship. We hope that subsequent research will confirm our preliminary observations. In conclusion, we found that: (1) in all our patients the highest hHGF values were observed at admission due to symptoms of acute coronary syndrome, (2) hHGF concentrations were reduced to normal values very quickly (within 5 h from the first measurement), (3) severe complications in the acute stage of STEMI most likely resulted in an additional increase in hHGF levels.
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